Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 6Thoracic 3Gastrointestinal 3Genitourinary 2Breast 2Sarcoma 1Gynecologic 1CNS 1

Conditions

Breast Neoplasms 48Fatigue 15Neoplasms 9Prostatic Neoplasms 7Depression 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Non-Hodgkin 6Leukemia, Lymphocytic, Chronic, B-Cell 6Hodgkin Disease 6Carcinoma, Ovarian Epithelial 6Testicular Neoplasms 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myeloid, Chronic-Phase 5Leukemia, Myeloid, Acute 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Hairy Cell 5Burkitt Lymphoma 5Blast Crisis 5Primary Myelofibrosis 4Pain 4Neuroblastoma 4Multiple Myeloma 4Lymphoma, T-Cell, Cutaneous 4Lung Neoplasms 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4

Interventions

pembrolizumab 44Cyclophosphamide 21Nivolumab 18fludarabine 10durvalumab 8Paclitaxel 8Magnetic Resonance Spectroscopy 8Interleukin-2 8Docetaxel 8aldesleukin 7Radiosurgery 7Ipilimumab 7spartalizumab 6poly ICLC 6fludarabine phosphate 6atezolizumab 6Specimen Handling 6Radiotherapy 6Carboplatin 6cemiplimab 5Drug Therapy 5Cisplatin 5Biopsy 5Temozolomide 4Immune Checkpoint Inhibitors 4tremelimumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3pazopanib 3avelumab 3Trastuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Therapeutics × Breast × Clear all
NCT06180460 2025-10-08

CALM: Managing Distress in Malignant Brain Cancer

Virginia Commonwealth University

Phase NA Completed
60 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡